Werewolf Therapeutics (HOWL)
(Real Time Quote from BATS)
$3.36 USD
-0.23 (-6.41%)
Updated Jun 6, 2024 10:42 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Werewolf Therapeutics, Inc. [HOWL]
Reports for Purchase
Showing records 1 - 20 ( 45 total )
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Listen For the HOWL During ASCO?24, as WTX-124 Takes Another Bite Out of Solid Tumors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q:24 Financials; WTX-124 and WTX-330 Updates On Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; WTX-124 and WTX-330 Updates Planned for Q2
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124?s Mono/Combo Data (1H24) Looks to Further Derisk Cytokine Masking Strategy; Reit Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; WTX-124 And WTX-330 Updates Planned for Q2
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An INDUKINE Tasting Menu-Highlights From Our Werewolf CMO Dinner
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Addition Interim WTX-124 Data 1H24; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124 Forms a New Narrative Towards Cytokine Therapies-Additional Detailed SITC?23 Data Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Hear that HOWL; Initial WTX-124 Proof of Concept Data
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC ?23 Abstract Highlights First Positive Clinical Signals For WTX-124, Along With Mechanistic Rationale
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
WTX-124?s Interim First-in-Human Data at SITC Looks to Improve IL-2?s Profile-Our Data Preview
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IL-2 Focused KOL Event Frames WTX-124?s Potential in On
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Werewolf Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Quick Takeaways from Our Fireside Chat with Werewolf Therapeutics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A